AstraZeneca and Daiichi Sankyo’s Enhertu Improves PFS in First-Line HER2-Mutant Advanced NSCLC in Phase III DESTINY-Lung04
Aug 17, 2026
View online
AstraZeneca and Daiichi Sankyo’s Enhertu Improves PFS in First-Line HER2-Mutant Advanced NSCLC in Phase III DESTINY-Lung04
International Urology Cancer Summit and OncoDaily Announce Strategic Partnership
Using Lung Function Data to Refine Pulmonary Toxicity Risk Before Thoracic Radiotherapy
Cancer Planners Forum 2026: Strengthening National Cancer Control Plans Worldwide
Vivek Subbiah: Rethinking the Unified Cancer of Unknown Primary Concept
Lenox Hill Hospital’s Brain Tumor Center Gala Raises More Than $1.6 Million to Advance Brain Tumor Research
Swim Against Cancer: Bartłomiej Kubkowski’s Historic 160-Km Baltic Crossing
Immunõ 2026: Global Virtual Congress on Immuno Oncology
ASH Global Research Award 2027
American Cancer Society Mission Boost Grants 2026
The AORTICHORG 3rd Quarterly Webinar
The CAN Monthly Membership Meeting Call
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
